SGYP Key Stats
- Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide 1:41 PM
- Synergy Pharmaceuticals Presents Plecanatide Results From a Large Multicenter Cl... 10:00 AM
- SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Fina... 3:12 AM
- SYNERGY PHARMACEUTICALS, INC. Financials May 17
- Due Diligence in Finding the Value of Pharmaceuticals: Expert Portfolio Manager ... May 16
- Synergy Pharma Posts Wider Loss May 15
- Synergy Pharma Posts Wider Loss - Analyst Blog Zacks May 15
- Synergy Pharmaceuticals Added to NASDAQ Biotechnology Index GlobeNewswire May 14
- SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statem... May 14
- SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Fina... May 10
SGYP Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Synergy Pharmaceuticals is up 14.81% over the last year vs S&P 500 Total Return up 31.95%, Ironwood Pharmaceuticals up 19.79%, and Forest Laboratories up 14.22%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for SGYP
Pro Report PDF for SGYP
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download SGYP Pro Report PDF
Pro Strategies Featuring SGYP
Did Synergy Pharmaceuticals make it into our Pro Portfolio Strategies?